<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556606</url>
  </required_header>
  <id_info>
    <org_study_id>CLNA-001-14F</org_study_id>
    <nct_id>NCT02556606</nct_id>
  </id_info>
  <brief_title>Ketamine for Treatment Resistant Late-Life Depression</brief_title>
  <official_title>Ketamine for Treatment Resistant Late-Life Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effectiveness of a single infusion of ketamine&#xD;
      (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive&#xD;
      Randomization, and to learn about how ketamine works in the body and brain in persons with&#xD;
      late-life treatment resistant depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aim: To identify the best performing condition across a single intravenous infusion&#xD;
      of ketamine (KET) 0.1 mg/kg, KET 0.25 mg/kg, KET 0.50 mg/kg) and midazolam (MID) 0.03 mg/kg&#xD;
      on Montgomery-Asberg Depression Rating Scale (MADRS) treatment response (at least a 50%&#xD;
      improvement in depression from baseline) 7 days after the infusion in up to 72 Veterans with&#xD;
      Late-Life Treatment Resistant Depression (LL-TRD) , using a triple blind (patient, rater,&#xD;
      anesthesiologist) Bayesian adaptive randomization design.&#xD;
&#xD;
      Hypothesis 1: Single KET 0.5 mg/kg infusion is superior to KET 0.1 mg/kg, KET 0.25 mg/kg, and&#xD;
      MID 0.03 mg/kg measured by the proportion of participants demonstrating &gt; 50% reduction on&#xD;
      MADRS scores 7 days post-treatment.&#xD;
&#xD;
      Secondary Aim: To evaluate the durability of day 7 treatment response across 3 sub-anesthetic&#xD;
      doses of a single KET (0.1 mg/kg, 0.25 mg/kg, and 0.50 mg/kg) and MID (0.03 mg/kg) infusion&#xD;
      in veterans with LL-TRD during a 4 week follow-up.&#xD;
&#xD;
      Hypothesis 2: a single KET 0.5 mg/kg infusion will be superior to a single infusion of KET&#xD;
      0.1 mg/kg, KET 0.25 mg/kg, and MID 0.03 mg/kg as measured by the proportion of participants&#xD;
      demonstrating &gt; 50% reduction on MADRS scores at 28 days post-infusion.&#xD;
&#xD;
      Tertiary Aim: To evaluate the immediate and longer-term safety and tolerability of the most&#xD;
      effective KET infusion relative to MID in vets with LL-TRD.&#xD;
&#xD;
      Hypothesis 3: KET infusion at the most effective dose will be safe and well tolerated&#xD;
      compared to MID, as assessed by psychoactive and general side effect rating scales during and&#xD;
      up to 4 weeks post study infusion.&#xD;
&#xD;
      Exploratory Aims:&#xD;
&#xD;
        1. To measure the effects of the most effective dose of KET relative to MID on&#xD;
           neurocognitive performance.&#xD;
&#xD;
        2. To measure the effects the most effective dose of KET relative to MID on peripheral&#xD;
           biomarkers of cellular plasticity and inflammation.&#xD;
&#xD;
        3. To measure the effects the most effective dose of KET relative to MID on resting-state&#xD;
           quantitative electroencephalography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>We use a Bayesian, adaptive, randomized design initially allocating subjects to 2 arms in a 1:3 ratio: ARM 1: MID 0.03 mg/kg (active placebo); ARM 2: four conditions KET 0.1 mg/kg, KET 0.25 mg/kg, KET 0.5 mg/kg or MID 0.03 mg/kg. After 1:1:1:1 allocation of the first 20 subjects to ARM 2, Bayesian adaptive randomization may stop for superiority, change randomization ratios and/or prune arms for futility based on the probability of a day 7 treatment response. ARM 1 remains open for allocation to ensure a placebo group sufficiently large for comparison with best dose KET. For analyses, MID of ARM 1 and ARM 2 will be combined so that there are 4 conditions (or arms) for final statistical analyses. We expected to enroll a maximum 72 patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Demonstrating at Least a 50% Reduction on Montgomery-Asberg Depression Rating Scale Scores</measure>
    <time_frame>at day 7 post-infusion</time_frame>
    <description>To determine the best performing intervention among three sub-anesthetic doses of a single ketamine (0.1 mg/kg, 0.25 mg/kg, and 0.50 mg/kg) and midazolam (0.03 mg/kg) in Veterans with LL-TRD as measured by the percentage of participants demonstrating at least a 50% reduction from pre-treatment baseline on Montgomery-Asberg Depression Rating Scale (MADRS; score range 0 - 60, higher scores meaning more severe depression) scores at 7 days post-infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Continuation From Day 7 to Day 28 Post-infusion of at Least a 50% Improvement in MADRS</measure>
    <time_frame>28 days post-infusion follow-up</time_frame>
    <description>Patients with a day 7 treatment response (at least a 50% improvement from baseline in Montgomery-Asberg Depression Rating Scale [MADRS]) are followed until day 28 post-infusion; day 7 non-responders are not followed. Outcome measure is the percentage of patients who continue to be responder at day 28, and is interpreted as a measure of durability of efficacy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Psychoactive Side Effect Rating Scales</measure>
    <time_frame>pre-infusion, 40 min, 120 min and 240 min on day of infusion</time_frame>
    <description>To evaluate the immediate and longer-term safety and tolerability of the most effective KET infusion (0.5 mg/kg) relative to midazolam (0.03 mg/kg) by assessing psychoactive side effect rating scales using the Clinician-Administered Dissociative States Scale (CADSS) during the day of infusion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Resting-state Quantitative Electroencephalography</measure>
    <time_frame>pre-infusion, 30 minutes, 60 minutes, 120 minutes, 240 minutes after start of infusion, and at 24 hours, 48 hours and 7 days post-infusion.</time_frame>
    <description>To measure the effects the most effective dose of KET (0.50 mg/kg) relative to MID (0.03 mg/kg) on resting-state quantitative electroencephalography. Pharmaco-EEG (12 minutes of alternating 1-minute eyes open and closed) will be assessed pre-infusion, 28 minutes after start of infusion, 60 minutes after start of infusion, and 2 and 3 hours after end of infusion and 1, 3, and 7 days after ketamine infusion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral Biomarkers of Cellular Plasticity</measure>
    <time_frame>day of the infusion at baseline, 120 minutes, 240 minutes, 8 hours, and 7 days post infusion and four weeks post infusion</time_frame>
    <description>To measure the effects the most effective dose of KET (0.50 mg/kg) relative to MID (0.03 mg/kg) on peripheral biomarkers of cellular plasticity by brain-derived neurotrophic factor (BDNF) measures from blood samples taken.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Treatment Resistant Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine 0.10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.25 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.50 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam 0.03 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg</description>
    <arm_group_label>Ketamine 0.10 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg</description>
    <arm_group_label>Ketamine 0.25 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg</description>
    <arm_group_label>Ketamine 0.50 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>single 40 min infusion of MID 0.03mg/Kg</description>
    <arm_group_label>Midazolam 0.03 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, 55 years of age,&#xD;
&#xD;
          -  Participants must fulfill DSM 5 criteria for a Major Depressive Episode (Unipolar),&#xD;
             based on a structured diagnostic interview, the DSM 5 M.I.N.I. 7.0&#xD;
&#xD;
          -  Participants must have a history of at least one previous episode of depression prior&#xD;
             to the current episode (recurrent MDD) or have chronic MDD (of at least two years'&#xD;
             duration),&#xD;
&#xD;
          -  Participants have not responded to two or more adequate trials of FDA-approved&#xD;
             antidepressants, determined by Antidepressant Treatment Response Questionnaire (ATRQ)&#xD;
             criteria.&#xD;
&#xD;
          -  Participants must score 14 or greater on the Quick Inventory of Depressive&#xD;
             Symptomatology-Self Report (QIDS-SR), and score 27 on the Montgomery Asberg Depression&#xD;
             Rating Scale (MADRS),&#xD;
&#xD;
          -  Each participant must have a level of understanding sufficient to agree to all tests&#xD;
             and examinations required by the protocol and must sign an informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients currently on fluoxetine,&#xD;
&#xD;
          -  History of schizophrenia, schizoaffective disorder or any psychotic disorder, or&#xD;
             bipolar disorder,&#xD;
&#xD;
          -  Documented history of a psychotic disorder in a first-degree relative,&#xD;
&#xD;
          -  Current diagnosis of obsessive-compulsive disorder (OCD) or eating disorder [bulimia&#xD;
             nervosa or anorexia nervosa],&#xD;
&#xD;
          -  Alcohol or substance use [except nicotine] within the preceding 6 months,&#xD;
&#xD;
          -  Patients with any clinically significant personality disorder that would, in the&#xD;
             investigator's judgment, preclude safe study participation,&#xD;
&#xD;
          -  Patients judged to be at serious and imminent suicidal or homicidal risk,&#xD;
&#xD;
          -  Serious, unstable medical illnesses including respiratory [obstructive sleep apnea, or&#xD;
             history of difficulty with airway management during previous anesthetics],&#xD;
             cardiovascular [including ischemic heart disease and uncontrolled hypertension], and&#xD;
             neurologic [including history of severe head injury],&#xD;
&#xD;
          -  For study entry, patients must be reasonable medical candidates for ketamine or&#xD;
             midazolam infusion, as determined by a board-certified physician co-investigator&#xD;
             during study Screening,&#xD;
&#xD;
          -  Clinically significant abnormal findings of laboratory parameters [including urine&#xD;
             toxicology screen for drugs of abuse], physical examination, or ECG,&#xD;
&#xD;
          -  Hypertension (systolic BP &gt;160 mm Hg or diastolic BP &gt;90 mm Hg),&#xD;
&#xD;
          -  Patients with one or more 11 seizures without a clear and resolved etiology,&#xD;
&#xD;
          -  Patients starting hormonal treatment (e.g., estrogen) in the 3 months prior to&#xD;
             Screening,&#xD;
&#xD;
          -  Past intolerance or hypersensitivity to ketamine, or history of recreational use of&#xD;
             phencyclidine (PCP) or ketamine,&#xD;
&#xD;
          -  Past intolerance or hypersensitivity to midazolam,&#xD;
&#xD;
          -  Age-related cognitive decline or mild dementia suggested by a score of &lt; 25 on the&#xD;
             Mini-Mental State Examination (MMSE) at Screening,&#xD;
&#xD;
          -  Patients taking medications with known activity at the N-methyl-D-aspartate receptor&#xD;
             (NMDA) or AMPA glutamate receptor [e.g., riluzole, amantadine, lamotrigine, memantine,&#xD;
             topiramate, dextromethorphan, D-cycloserine], or the muopioid receptor,&#xD;
&#xD;
          -  Patients taking any of the following medications: St John's Wort, theophylline,&#xD;
             tramadol, metrizamide,&#xD;
&#xD;
          -  Patients who demonstrate &gt; 25% decrease in depressive symptoms as reflected by the&#xD;
             QIDS-SR score from Screening to Randomization,&#xD;
&#xD;
          -  Patients who have received electroconvulsive therapy (ECT) in the past 6 months prior&#xD;
             to Screening,&#xD;
&#xD;
          -  Patients currently receiving treatment with vagus nerve stimulation (VNS) or&#xD;
             repetitive transcranial stimulation (rTMS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Mathew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michael E. DeBakey VA Medical Center, Houston, TX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center, Houston, TX</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <results_first_submitted>April 13, 2021</results_first_submitted>
  <results_first_submitted_qc>July 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2021</results_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ketamine</keyword>
  <keyword>depression</keyword>
  <keyword>treatment resistant</keyword>
  <keyword>treatment resistant depression</keyword>
  <keyword>late life depression</keyword>
  <keyword>depression in the elderly</keyword>
  <keyword>geriatric depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02556606/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine 0.10 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg&#xD;
Ketamine: randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg</description>
        </group>
        <group group_id="P2">
          <title>Ketamine 0.25 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg&#xD;
Ketamine: randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg</description>
        </group>
        <group group_id="P3">
          <title>Ketamine 0.50 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg&#xD;
Ketamine: randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg</description>
        </group>
        <group group_id="P4">
          <title>Midazolam 0.03 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg&#xD;
Midazolam: single 40 min infusion of MID 0.03mg/Kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine 0.10 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of KET 0.1 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Ketamine 0.25 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of KET 0.25 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Ketamine 0.50 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of KET 0.50 mg/kg</description>
        </group>
        <group group_id="B4">
          <title>Midazolam 0.03 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of MID 0.03 mg/kg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.75" spread="5.54"/>
                    <measurement group_id="B2" value="61.8" spread="6.06"/>
                    <measurement group_id="B3" value="60.91" spread="4.97"/>
                    <measurement group_id="B4" value="62.15" spread="5.54"/>
                    <measurement group_id="B5" value="62.24" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Demonstrating at Least a 50% Reduction on Montgomery-Asberg Depression Rating Scale Scores</title>
        <description>To determine the best performing intervention among three sub-anesthetic doses of a single ketamine (0.1 mg/kg, 0.25 mg/kg, and 0.50 mg/kg) and midazolam (0.03 mg/kg) in Veterans with LL-TRD as measured by the percentage of participants demonstrating at least a 50% reduction from pre-treatment baseline on Montgomery-Asberg Depression Rating Scale (MADRS; score range 0 - 60, higher scores meaning more severe depression) scores at 7 days post-infusion.</description>
        <time_frame>at day 7 post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.10 mg/kg</title>
            <description>randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg&#xD;
Ketamine: randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.25 mg/kg</title>
            <description>randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg&#xD;
Ketamine: randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 0.50 mg/kg</title>
            <description>randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg&#xD;
Ketamine: randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg</description>
          </group>
          <group group_id="O4">
            <title>Midazolam 0.03 mg/kg</title>
            <description>randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg&#xD;
Midazolam: single 40 min infusion of MID 0.03mg/Kg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Demonstrating at Least a 50% Reduction on Montgomery-Asberg Depression Rating Scale Scores</title>
          <description>To determine the best performing intervention among three sub-anesthetic doses of a single ketamine (0.1 mg/kg, 0.25 mg/kg, and 0.50 mg/kg) and midazolam (0.03 mg/kg) in Veterans with LL-TRD as measured by the percentage of participants demonstrating at least a 50% reduction from pre-treatment baseline on Montgomery-Asberg Depression Rating Scale (MADRS; score range 0 - 60, higher scores meaning more severe depression) scores at 7 days post-infusion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Continuation From Day 7 to Day 28 Post-infusion of at Least a 50% Improvement in MADRS</title>
        <description>Patients with a day 7 treatment response (at least a 50% improvement from baseline in Montgomery-Asberg Depression Rating Scale [MADRS]) are followed until day 28 post-infusion; day 7 non-responders are not followed. Outcome measure is the percentage of patients who continue to be responder at day 28, and is interpreted as a measure of durability of efficacy.</description>
        <time_frame>28 days post-infusion follow-up</time_frame>
        <population>Day 7 responders were followed until day 28 post-infusion or until relapse</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.10 mg/kg</title>
            <description>randomly assigned to a single 40 min infusion of KET 0.1 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.25 mg/kg</title>
            <description>randomly assigned to a single 40 min infusion of KET 0.25 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 0.50 mg/kg</title>
            <description>randomly assigned to a single 40 min infusion of KET 0.50 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>Midazolam 0.03 mg/kg</title>
            <description>randomly assigned to a single 40 min infusion of MID 0.03 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Continuation From Day 7 to Day 28 Post-infusion of at Least a 50% Improvement in MADRS</title>
          <description>Patients with a day 7 treatment response (at least a 50% improvement from baseline in Montgomery-Asberg Depression Rating Scale [MADRS]) are followed until day 28 post-infusion; day 7 non-responders are not followed. Outcome measure is the percentage of patients who continue to be responder at day 28, and is interpreted as a measure of durability of efficacy.</description>
          <population>Day 7 responders were followed until day 28 post-infusion or until relapse</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Psychoactive Side Effect Rating Scales</title>
        <description>To evaluate the immediate and longer-term safety and tolerability of the most effective KET infusion (0.5 mg/kg) relative to midazolam (0.03 mg/kg) by assessing psychoactive side effect rating scales using the Clinician-Administered Dissociative States Scale (CADSS) during the day of infusion.</description>
        <time_frame>pre-infusion, 40 min, 120 min and 240 min on day of infusion</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Resting-state Quantitative Electroencephalography</title>
        <description>To measure the effects the most effective dose of KET (0.50 mg/kg) relative to MID (0.03 mg/kg) on resting-state quantitative electroencephalography. Pharmaco-EEG (12 minutes of alternating 1-minute eyes open and closed) will be assessed pre-infusion, 28 minutes after start of infusion, 60 minutes after start of infusion, and 2 and 3 hours after end of infusion and 1, 3, and 7 days after ketamine infusion.</description>
        <time_frame>pre-infusion, 30 minutes, 60 minutes, 120 minutes, 240 minutes after start of infusion, and at 24 hours, 48 hours and 7 days post-infusion.</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peripheral Biomarkers of Cellular Plasticity</title>
        <description>To measure the effects the most effective dose of KET (0.50 mg/kg) relative to MID (0.03 mg/kg) on peripheral biomarkers of cellular plasticity by brain-derived neurotrophic factor (BDNF) measures from blood samples taken.</description>
        <time_frame>day of the infusion at baseline, 120 minutes, 240 minutes, 8 hours, and 7 days post infusion and four weeks post infusion</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine 0.10 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg&#xD;
Ketamine: randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg</description>
        </group>
        <group group_id="E2">
          <title>Ketamine 0.25 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg&#xD;
Ketamine: randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg</description>
        </group>
        <group group_id="E3">
          <title>Ketamine 0.50 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg&#xD;
Ketamine: randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg</description>
        </group>
        <group group_id="E4">
          <title>Midazolam 0.03 mg/kg</title>
          <description>randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg&#xD;
Midazolam: single 40 min infusion of MID 0.03mg/Kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <description>One participant made a suicide attempt four days after midazolam infusion. The event was determined unrelated to the intervention because this participant scored zero on the Columbia Suicide Severity Rating Scale one day before the attempt</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac complaints</sub_title>
                <description>Collected with the Patient Reported Inventory of Side Effects (PRISE)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye or ear complaints</sub_title>
                <description>Collected with the Patient Reported Inventory of Side Effects (PRISE)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal complaints</sub_title>
                <description>Using the Patient Reported Inventory of Side Effects (PRISE) as a score of 1 or 2 (mild to moderate adverse event); scores over 2 indicate serious adverse event and are not reported in this section. Collected to day 7 due to smaller sample to day 28.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep complaints</sub_title>
                <description>Collected with the Patient Reported Inventory of Side Effects (PRISE)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Other complaints</sub_title>
                <description>Collected with the Patient Reported Inventory of Side Effects (PRISE)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system complaints</sub_title>
                <description>Collected with the Patient Reported Inventory of Side Effects (PRISE)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital or urinary complaints</sub_title>
                <description>Collected with the Patient Reported Inventory of Side Effects (PRISE)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sexual functioning complaints</sub_title>
                <description>Collected with the Patient Reported Inventory of Side Effects (PRISE)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin complaints</sub_title>
                <description>Collected with the Patient Reported Inventory of Side Effects (PRISE)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marijn Lijffijt, PhD</name_or_title>
      <organization>Michael E. DeBakey VA Medical Center</organization>
      <phone>3618274395</phone>
      <email>marijn.lijffijt@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

